Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) is pursuing a public-market listing for its SkinJect subsidiary through a proposed merger with a special purpose acquisition company that values the …
Medicus Pharma Pursues $135 Million SkinJect SPAC Deal Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is pursuing a public listing for its SkinJect subsidiary through a proposed merger with a special purpose acquisition company that values the …
Medicus Seeks $135 Million Valuation in SkinJect SPAC Deal Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has regained compliance with Nasdaq’s minimum share price requirement, resolving a listing deficiency that threatened its continued eligibility to trade on the …
Medicus Pharma Regains Nasdaq Minimum Share Price Compliance Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has raised approximately $90 million through equity and debt financing over three years to build a diversified drug-development portfolio, leaving the biotechnology …
ICYMI: Medicus Pharma Faces Clinical Test After Raising $90 Million Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) is concentrating its drug-development investments on targeted cancer therapies while pursuing partnerships to limit future financing requirements, a strategic shift that follows …
Medicus Pharma Shifts Focus to Oncology Amid Stock Volatility Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has proposed a redesigned late-stage development program for its prostate cancer drug Teverelix that could reduce planned enrollment by about 60% while …
ICYMI: Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) will end internally funded development of SkinJect for sporadic nodular basal cell carcinoma and concentrate its clinical spending on Gorlin syndrome, narrowing …
ICYMI: Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma is ending further development of SkinJect for sporadic nodular basal cell carcinoma and concentrating its investment on an FDA-authorized Phase 2b study in Gorlin syndrome, …
Medicus Narrows SkinJect Program to Gorlin Syndrome Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) selected the 200-mcg dose of its SkinJect patch for further development after completing a Phase 2 basal cell carcinoma study, supporting the …
ISYMI: Medicus Picks 200-Mcg SkinJect Dose for Gorlin Program Read More